Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 7, 2009
Herceptin has proven to be a life-saving drug for women with HER2+ breast cancer, which makes up 20 percent to 25 percent of all cases. But it has not been known whether the agent should be given with, or after, chemotherapy in women who have already had surgery to remove tumors. The answer is now known, based on a key trial headed by Mayo Clinic researchers, who tested the two different regimens head-to-head. Lead investigator Edith Perez, M.D., Professor of Medicine at Mayo Clinics campus in Jacksonville, Fla., shares more on this study.